213 related articles for article (PubMed ID: 27892610)
1. JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus.
Klaeschen AS; Wolf D; Brossart P; Bieber T; Wenzel J
Exp Dermatol; 2017 Aug; 26(8):728-730. PubMed ID: 27892610
[TBL] [Abstract][Full Text] [Related]
2. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.
Fetter T; Smith P; Guel T; Braegelmann C; Bieber T; Wenzel J
Front Immunol; 2020; 11():344. PubMed ID: 32194562
[TBL] [Abstract][Full Text] [Related]
3. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.
Wenzel J; van Holt N; Maier J; Vonnahme M; Bieber T; Wolf D
J Invest Dermatol; 2016 Jun; 136(6):1281-1283. PubMed ID: 26916391
[No Abstract] [Full Text] [Related]
4. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
[TBL] [Abstract][Full Text] [Related]
5. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Braegelmann C; Hölzel M; Ludbrook V; Dickson M; Turan N; Ferring-Schmitt S; Sternberg S; Bieber T; Kuhn A; Wenzel J
Exp Dermatol; 2016 May; 25(5):375-9. PubMed ID: 26910509
[TBL] [Abstract][Full Text] [Related]
6. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus.
Wenzel J; Wörenkämper E; Freutel S; Henze S; Haller O; Bieber T; Tüting T
J Pathol; 2005 Mar; 205(4):435-42. PubMed ID: 15685590
[TBL] [Abstract][Full Text] [Related]
7. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
Febvre-James M; Lecureur V; Augagneur Y; Mayati A; Fardel O
Int Immunopharmacol; 2018 Jan; 54():354-365. PubMed ID: 29202299
[TBL] [Abstract][Full Text] [Related]
8. Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.
Scholtissek B; Zahn S; Maier J; Klaeschen S; Braegelmann C; Hoelzel M; Bieber T; Barchet W; Wenzel J
J Invest Dermatol; 2017 Jul; 137(7):1484-1492. PubMed ID: 28351661
[TBL] [Abstract][Full Text] [Related]
9. NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus.
Vorwerk G; Zahn S; Bieber T; Wenzel J
Exp Dermatol; 2021 Jun; 30(6):847-852. PubMed ID: 33687107
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B
Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666
[No Abstract] [Full Text] [Related]
11. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
12. High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.
Wenzel J; Landmann A; Vorwerk G; Kuhn A
Exp Dermatol; 2018 Jan; 27(1):95-97. PubMed ID: 28833566
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.
Niebel D; de Vos L; Fetter T; Brägelmann C; Wenzel J
Am J Clin Dermatol; 2023 Jul; 24(4):521-540. PubMed ID: 37140884
[TBL] [Abstract][Full Text] [Related]
14. Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: An evidence-based review.
Abduelmula A; Sood S; Mufti A; Hinek A; Yeung J
J Am Acad Dermatol; 2023 Jul; 89(1):130-131. PubMed ID: 36935014
[No Abstract] [Full Text] [Related]
15. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
[TBL] [Abstract][Full Text] [Related]
16. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus.
Naschberger E; Wenzel J; Kretz CC; Herrmann M; Stürzl M; Kuhn A
Exp Dermatol; 2011 Feb; 20(2):102-6. PubMed ID: 21121962
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis.
Jacquemin C; Rambert J; Guillet S; Thiolat D; Boukhedouni N; Doutre MS; Darrigade AS; Ezzedine K; Blanco P; Taieb A; Boniface K; Seneschal J
Br J Dermatol; 2017 Nov; 177(5):1367-1375. PubMed ID: 28380264
[TBL] [Abstract][Full Text] [Related]
19. Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
Kayaoglu B; Kasap N; Yilmaz NS; Charbonnier LM; Geckin B; Akcay A; Eltan SB; Ozturk G; Ozen A; Karakoc-Aydiner E; Chatila TA; Gursel M; Baris S
J Clin Immunol; 2021 May; 41(4):769-779. PubMed ID: 33475942
[TBL] [Abstract][Full Text] [Related]
20. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
